|
2020 Other Outputs Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a mouse model of early heart failure without diabetesYoung, Sophia L., Ryan, Lydia, Mullins, Thomas P., Flint, Melanie, Steane, Sarah E., Walton, Sarah L., Bielefeldt-Ohmann, Helle, Carter, David A., Reichelt, Melissa E. and Gallo, Linda A. (2020). Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a mouse model of early heart failure without diabetes. |
